OrbusNeich: Create

Genous

• The Approach
  • Bare Metal Stents
  • Drug Eluting Stents
  • Genous R stent
• Mechanism of Action
• Coating Process
• In Vivo Porcine Results
• Optimization
  • Healing Response
  • Endothelium's Role
• Protect Against Thrombus
• Clinical Studies
  • HEALING Program
  • HEALING II Trial Design
  • HEALING IIb Trial Design
• FAQ
• Case Spotlights
  • First in Asian Patient
  • First in e-HEALING
  • Totally Occluded LAD
  • Direct Stenting
  • First Prophylactic Implantation
  • CTO Case
• Scientific Literature
• Scientific Presentations
  • EuroPCR 2008 HEALING Symposium Presentations
  • HEALING II SingLive 2006
  • HEALING II TCT 2005
• Product Information
  • Stent Specifications
  • Balloon Specifications
  • Surface Specifications
  • Compliance Chart
  • Ordering Information

FAQ

What differentiates the EPC approach from the current drug eluting technology to prevent restenosis?

What are EPCs?

How confident are you that you will see the same or better results in humans than in your porcine in vivo results?

If EPCs naturally migrate toward injury, why don’t they form an endothelial monolayer over the stent on their own?

How do we know the attached cells are EPCs?

What type of antibodies are used with Genous?

What is the status of EPC capture development?.